Treatment options for advanced prostate cancer (PCa) are broadly categorized into radiotherapy, taxane-based chemotherapeutics and suppression of the androgen signaling axis via androgen deprivation therapy (ADT) and androgen receptor signaling inhibitors (ARSI) [4]. The gene discussed is AR; the disease is posterior cortical atrophy.